biostudies-literatureUnknown10(1)Rossi E<h4>Background</h4>In advanced non-small cell lung cancer (NSCLC) a recent meta-analysis confirms circulating tumour cells (CTCs) as an independent prognostic indicator of progression-free survival (PFS) and overall survival (OS). However, further investigations are necessary to predict and dynamically monitor the therapy in NSCLC patients using CTCs. To this aim, we combined the classical standard assay (SA) with an expanded cytokeratins profile (EA) and quantified the expression of EML4-ALK fusion protein in CTCs.<h4>Methods</h4>The CellSearch (CS) platform-first marked <i>in vitro</i> diagnostic use (IVD) from Food and Drug Administration (FDA), and "gold standard" for quantifying CTCs - detects EpCAM and cytokeratins (CKs) 8, 18, and 19. Since NSCLC shows different CKs profile, we custTranslational lung cancer research80-92https://www.ebi.ac.uk/biostudies/studies/S-EPMC7867748biostudies-literatureA fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients.PMC7867748Aieta MPossidente LRossi ETartarone AFacchinetti AFiduccia PZamarchi RSantini DMinicuci NPezzuto ALudovini VUlivi PfalseA fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients.<h4>Background</h4>In advanced non-small cell lung cancer (NSCLC) a recent meta-analysis confirms circulating tumour cells (CTCs) as an independent prognostic indicator of progression-free survival (PFS) and overall survival (OS). However, further investigations are necessary to predict and dynamically monitor the therapy in NSCLC patients using CTCs. To this aim, we combined the classical standard assay (SA) with an expanded cytokeratins profile (EA) and quantified the expression of EML4-ALK fusion protein in CTCs.<h4>Methods</h4>The CellSearch (CS) platform-first marked <i>in vitro</i> diagnostic use (IVD) from Food and Drug Administration (FDA), and "gold standard" for quantifying CTCs - detects EpCAM and cytokeratins (CKs) 8, 18, and 19. Since NSCLC shows different CKs profile, we cust2021-01-01T00:00:00Z2021 Jan2025-04-26T18:28:47.508Z2025-02-19T01:41:15.25ZS-EPMC78677483356929510.21037/tlcr-20-855